🇺🇸 Rasigiline in United States
7 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 7
Most-reported reactions
- Acute Myocardial Infarction — 1 report (14.29%)
- Cardiogenic Shock — 1 report (14.29%)
- Constipation — 1 report (14.29%)
- Diabetes Mellitus Inadequate Control — 1 report (14.29%)
- Drug Ineffective — 1 report (14.29%)
- Paraganglion Neoplasm — 1 report (14.29%)
- Sinus Tachycardia — 1 report (14.29%)
Other Other approved in United States
Frequently asked questions
Is Rasigiline approved in United States?
Rasigiline does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Rasigiline in United States?
Celgene is the originator. The local marketing authorisation holder may differ — check the official source linked above.